Climb Bio Inc

Thomas Basil’s 10b5‑1 sell‑off adds liquidity, not panic, to Climb Bio – a biotech with strong neurology pipeline and rising stock. Read why it may not spell trouble.

Climb Bio CFO’s 142,500‑share option exercise signals executive confidence in mid‑term growth—watch upcoming clinical milestones and insider moves for investment insight.